FINGOLIMOD - fingolimod capsule
CivicaScript LLC
----------
Fingolimod [fin gol' i mod]
capsules, for oral use
Read this Medication Guide before you start taking fingolimod and each time you get a refill. There may be new information. If you are the parent of a child who is being treated with fingolimod, the following information applies to your child. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
What is the most important information I should know about fingolimod?
Fingolimod may cause serious side effects, including:
1. Slow heart rate (bradycardia or bradyarrhythmia) when you start taking fingolimod.
Fingolimod can cause your heart rate to slow down, especially after you take your first dose. You will have a test, to check the electrical activity of your heart called an electrocardiogram (ECG), before you take your first dose of fingolimod.
All adults and children will be observed by a healthcare professional for at least 6 hours after taking their first dose of fingolimod capsules. Children should also be observed by a healthcare professional for at least 6 hours after taking their first dose of 0.5 mg of fingolimod when switching from the 0.25 mg dose.
After you take your first dose of fingolimod, and after a child takes their first dose of 0.5 mg of fingolimod when switching from the 0.25 mg dose:
○ dizziness
○ tiredness
○ feeling like your heart is beating slowly or skipping beats
○ chest pain
Your slow heart rate will usually return to normal within 1 month after you start taking fingolimod. Call your healthcare provider or go to the nearest hospital emergency room right away if you have any symptoms of a slow heart rate.
If you miss 1 or more doses of fingolimod, you may need to be observed by a healthcare professional when you take your next dose. Call your healthcare provider if you miss a dose of fingolimod. See “How should I take fingolimod?"
2. Pregnancy. Please consult your healthcare provider before getting pregnant. You should avoid becoming pregnant while taking fingolimod or in the two months after you stop taking it because of the risk of harm to the baby.
3. Infections. Fingolimod can increase your risk of serious infections that can be life-threatening and cause death. You should not receive live vaccines during treatment with fingolimod and for 2 months after you stop taking fingolimod. Talk to your healthcare provider before you receive a vaccine during treatment and for 2 months after treatment with fingolimod. If you receive a live vaccine, you may get the infection the vaccine was meant to prevent. Vaccines may not work as well when given during treatment with fingolimod. Human Papilloma Virus (HPV). Due to risk of HPV infection please consult your healthcare provider for routine pap smear.
Fingolimod lowers the number of white blood cells (lymphocytes) in your blood. This will usually go back to normal within 2 months of stopping treatment. Your healthcare provider may do a blood test to check your white blood cells before you start taking fingolimod. Call your healthcare provider right away if you have any of these symptoms of an infection during treatment with fingolimod and for 2 months after your last dose of fingolimod:
4. Progressive multifocal leukoencephalopathy (PML). PML is a rare brain infection that usually leads to death or severe disability. If PML happens, it usually happens in people with weakened immune systems but has happened in people who do not have weakened immune systems. Symptoms of PML get worse over days to weeks. Call your healthcare provider right away if you have any new or worsening symptoms of PML, that have lasted several days, including:
5. A problem with your vision called macular edema. Macular edema can cause some of the same vision symptoms as a multiple sclerosis (MS) attack (optic neuritis). You may not notice any symptoms with macular edema. If macular edema happens, it usually starts in the first 3 to 4 months after you start taking fingolimod but can happen at any time. Your healthcare provider should test your vision around the time you start taking fingolimod, 3 to 4 months after you start taking fingolimod, periodically while you continue taking fingolimod, and any time you notice vision changes during treatment with fingolimod. Your risk of macular edema is higher if you have diabetes or have had an inflammation of your eye called uveitis.
Call your healthcare provider right away if you have any of the following symptoms:
What is fingolimod?
Fingolimod is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults and children 10 years of age and older.
It is not known if fingolimod is safe and effective in children under 10 years of age.
Who should not take fingolimod?
Do not take fingolimod if you:
Talk to your healthcare provider before taking fingolimod if you have any of these conditions, or do not know if you have any of these conditions.
What should I tell my healthcare provider before taking fingolimod?
Before you take fingolimod, tell your healthcare provider about all your medical conditions, including if you had or now have:
o You should stop taking fingolimod 2 months before trying to become pregnant.
o If you are a female who can become pregnant, you should use effective birth control during your treatment with fingolimod and for at least 2 months after you stop taking fingolimod.
• are breastfeeding or plan to breastfeed. It is not known if fingolimod passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take fingolimod.
Tell your healthcare provider about all the medicines you take or have recently taken, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Especially tell your healthcare provider if you take medicines that affect your immune system, including corticosteroids, or have taken them in the past.
Know the medicines you take. Keep a list of your medicines with you to show your healthcare provider and pharmacist when you get a new medicine.
Using fingolimod and other medicines together may affect each other causing serious side effects.
How should I take fingolimod?
What are possible side effects of fingolimod?
Fingolimod can cause serious side effects, including:
○ sudden severe headache
○ sudden confusion
○ sudden loss of vision or other changes in your vision
○ seizure
○ nausea
○ vomiting
○ stomach pain
○ tiredness
○ loss of appetite
○ your skin or the whites of your eyes turn yellow
○ dark urine
The most common side effects of fingolimod include:
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all of the possible side effects of fingolimod. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store fingolimod capsules?
General information about the safe and effective use of fingolimod.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use fingolimod for a condition for which it was not prescribed. Do not give fingolimod to other people, even if they have the same symptoms that you have. It may harm them.
This Medication Guide summarizes the most important information about fingolimod. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about fingolimod that is written for health professionals.
What are the ingredients in fingolimod capsules?
0.5 mg capsules
Active ingredient: fingolimod hydrochloride
Inactive ingredients: dibasic calcium phosphate, magnesium stearate and empty hard gelatin capsules. The hard gelatin capsules contain gelatin, titanium dioxide, yellow iron oxide, black imprinting ink and yellow ink. The imprinting ink contains propylene glycol, and shellac, and additionally the black ink contains black iron oxide, and potassium hydroxide, and the yellow ink contains yellow iron oxide.
Distributed by:
CivicaScript, LLC
Lehi, Utah 84048
Manufactured by:
Alkem Laboratories Ltd.,
Mumbai - 400 013, INDIA.
This Medication Guide has been approved by the U.S. Food and Drug Administration.
Revised: August 2025
PT 4005